194 related articles for article (PubMed ID: 19215676)
1. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
[TBL] [Abstract][Full Text] [Related]
2. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
Tuzun Y; Yilmaz S; Dursun M; Canoruc F; Celik Y; Cil T; Boyraz T
J Int Med Res; 2009; 37(1):87-95. PubMed ID: 19215677
[TBL] [Abstract][Full Text] [Related]
3. Comparative Assessment of Two Strategies for Interpreting Tumor Markers in Ascitic Effusions.
Trapé J; Sant F; Montesinos J; Arnau A; Sala M; Figols C; Franquesa J; Esteve-Valverde E; Pérez R; Aligué J; Catot S; Casado E; Domenech M; Trapé-Ubeda J; Bergós C; Vida F; Sort P; Bonet M; Ruiz D; González-Fernández C; Ordeig J; Molina R
In Vivo; 2020; 34(2):715-722. PubMed ID: 32111775
[TBL] [Abstract][Full Text] [Related]
4. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
5. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites.
Alexandrakis MG; Moschandrea J; Kyriakou DS; Alexandraki R; Kouroumalis E
Int J Biol Markers; 2001; 16(1):45-9. PubMed ID: 11288954
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites.
Chen SJ; Wang SS; Lu CW; Chao Y; Lee FY; Lee SD; Wu SL; Cherng KL; Lo KJ
J Gastroenterol Hepatol; 1994; 9(4):396-400. PubMed ID: 7948823
[TBL] [Abstract][Full Text] [Related]
7. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.
Kaleta EJ; Tolan NV; Ness KA; O'Kane D; Algeciras-Schimnich A
Clin Biochem; 2013 Jun; 46(9):814-8. PubMed ID: 23454392
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites.
Trapé J; Gurt G; Franquesa J; Montesinos J; Arnau A; Sala M; Sant F; Casado E; Ordeig JM; Bergos C; Vida F; Sort P; Isava Á; González M; Molina R
Anticancer Res; 2015 Oct; 35(10):5655-60. PubMed ID: 26408739
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
11. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
12. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
[TBL] [Abstract][Full Text] [Related]
13. ASCITIC AND SERUM LEVELS OF TUMOR BIOMARKERS (CA 72-4, CA 19-9, CEA AND CA 125) IN DISCRIMINATION OF CAUSE OF ASCITES: A PROSPECTIVE STUDY.
Jain T; Ram S; Kumar H; Saroch A; Sharma V; Singh H
Arq Gastroenterol; 2022; 59(2):198-203. PubMed ID: 35830029
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and insulin-like growth factor-1 in differential diagnosis of ascites.
Abdel-Razik A; Eldars W; Elhelaly R; Elzehery R
J Gastroenterol Hepatol; 2016 Nov; 31(11):1868-1873. PubMed ID: 27010362
[TBL] [Abstract][Full Text] [Related]
15. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.
Antonangelo L; Sales RK; Corá AP; Acencio MM; Teixeira LR; Vargas FS
Curr Oncol; 2015 Oct; 22(5):e336-41. PubMed ID: 26628873
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.
Jung M; Jeung HC; Lee SS; Park JY; Hong S; Lee SH; Noh SH; Chung HC; Rha SY
J Cancer Res Clin Oncol; 2010 Apr; 136(4):517-26. PubMed ID: 19774395
[TBL] [Abstract][Full Text] [Related]
17. (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
Bala L; Sharma A; Yellapa RK; Roy R; Choudhuri G; Khetrapal CL
NMR Biomed; 2008 Jul; 21(6):606-14. PubMed ID: 18205245
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites.
Sun J; Chang YX; Niu CY
Tumour Biol; 2017 Nov; 39(11):1010428317726840. PubMed ID: 29130388
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
